From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Unity Biotechnology Inc (NASDAQ:UBX) stock has reached a 52-week high, trading at $2.02, signaling a period of robust ...

Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

Unity Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 76.03%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

OpenAI CEO Sam Altman backs Retro Biosciences, a San Francisco-based biotech start-up that wants to extend human lifespan by ...

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging ...

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic ...

Stock analysts at Chardan Capital started coverage on shares of Unity Biotechnology (NASDAQ:UBX – Get Free Report) in a research note issued to investors on Friday, Marketbeat.com reports. The firm ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.